INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST

Aims We evaluated the pharmacokinetics and pharmacodynamics of oral MK -462 in comparison with oral sumatriptan in healthy male volunteers. M ethods Sixteen healthy male volunteers were studied in a rising, singl e dose, alternating panel design with eight subjects per panel. Matchi ng placebo was administered to two of eight study subjects at each dos e level of MK-462 in a randomized, double-blind fashion. Results MK-46 2 was rapidly absorbed with a median t(max) of 1.3 h (range 1-3 h) vs a t(max) for sumatriptan of 2.5 h (range 1-4 h, P<0.001). Administrati on of either MK-462 or sumatriptan produced maximal mean elevations of 5-10 mmHg in systolic and diastolic blood pressures without effect on heart rate; the changes occurred sooner following MK-462, consistent with more rapid absorption. Both MK-462 and sumatriptan provoked mild increases in serum growth hormone without any effect on serum prolacti n concentrations. The most commonly reported symptom following MK-462 was drowsiness. Conclusions These results indicate that the novel 5-HT 1D agonist, MK-462, is rapidly absorbed following oral administration and warrants further investigation of its utility in the treatment of acute migraine.